Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
HGS-ETR2-ST02: A phase 1 clinical trial of HGS-ETR2, a fully-human activating monoclonal antibody to TRAIL-R2, in patients with advanced solid tumors. Sarantopoulos, J., Wakelee, H., Mita, M., Fitzgerald, A., Hill, M., Fox, N. L., Howard, T., Ullrich, S., Tolcher, A. W., Sikic, B. AMER ASSOC CANCER RESEARCH. 2005: 9104S
View details for Web of Science ID 000234382701142